MNG983
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.523
- CHOLESTEROL_HOMEOSTASIS+0.352
- WNT_BETA_CATENIN_SIGNALING+0.328
- MYC_TARGETS_V2+0.327
- TGF_BETA_SIGNALING+0.322
- ANGIOGENESIS+0.320
- UV_RESPONSE_DN+0.318
- MITOTIC_SPINDLE+0.297
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.278
- INFLAMMATORY_RESPONSE+0.267
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.341
- ALLOGRAFT_REJECTION-0.267
- PEROXISOME-0.164
- OXIDATIVE_PHOSPHORYLATION-0.154
- INTERFERON_ALPHA_RESPONSE-0.095
- SPERMATOGENESIS-0.091
- PANCREAS_BETA_CELLS-0.087
- PI3K_AKT_MTOR_SIGNALING-0.074
- BILE_ACID_METABOLISM-0.067
- XENOBIOTIC_METABOLISM-0.067
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A201-01A-11R-A14M-07 | — | A | 0.783 |
| 2 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.778 |
| 3 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.757 |
| 4 | TCGA-98-8020-01A-11R-2247-07 | — | cohortSQ1 | 0.754 |
| 5 | TCGA-34-5928-01A-11R-1820-07 | — | cohortSQ1 | 0.743 |
| 6 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.735 |
| 7 | TCGA-CN-5355-01A-01R-1436-07 | — | — | 0.714 |
| 8 | SRR27320688 | — | — | 0.713 |
| 9 | TCGA-CR-7365-01A-11R-2016-07 | — | — | 0.706 |
| 10 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.705 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.523 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.352 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.328 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.327 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.322 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.318 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.297 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.278 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.267 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.245 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.227 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.216 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.215 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.212 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.202 | Inavolisib | — uncovered |
| HYPOXIA | 0.191 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.189 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.186 | Inavolisib | — uncovered |